|
gptkbp:instanceOf
|
Controlled substance category
|
|
gptkbp:abusePotential
|
Low relative to Schedule III drugs
|
|
gptkbp:controlledSubstanceActSection
|
21 U.S.C. § 812(b)(4)
|
|
gptkbp:definedIn
|
gptkb:Controlled_Substances_Act_(United_States)
|
|
gptkbp:equivalentTo
|
Schedule IV (Convention on Psychotropic Substances)
|
|
gptkbp:example
|
gptkb:Alprazolam
gptkb:Clonazepam
gptkb:Diazepam
gptkb:Lorazepam
gptkb:Phenobarbital
gptkb:Tramadol
gptkb:Zolpidem
gptkb:Butorphanol
gptkb:Clobazam
gptkb:Modafinil
gptkb:Quazepam
gptkb:Suvorexant
gptkb:Carisoprodol
gptkb:Eszopiclone
gptkb:Chlordiazepoxide
gptkb:Midazolam
gptkb:Temazepam
Difenoxin/atropine
Mazindol
Phentermine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Schedule IV drugs
|
|
gptkbp:medicalUse
|
Accepted medical use in the United States
|
|
gptkbp:penaltyForIllegalPossession
|
Varies by jurisdiction
|
|
gptkbp:prescriptionRequirement
|
Prescription only
|
|
gptkbp:regulates
|
gptkb:Drug_Enforcement_Administration
|
|
gptkbp:scheduleLevel
|
IV
|
|
gptkbp:bfsParent
|
gptkb:Title_II:_Controlled_Substances_Act
gptkb:Controlled_Substances_Act_(US)
|
|
gptkbp:bfsLayer
|
7
|